J D Campbell

Summary

Affiliation: University of Maryland
Country: USA

Publications

  1. doi request reprint Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV
    James D Campbell
    Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda
    Am J Prev Med 44:S63-9. 2013
  2. pmc Timing of therapy for latent tuberculosis infection among immigrants presenting to a U.S. public health clinic: a retrospective study
    Kathleen R Page
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    BMC Public Health 8:158. 2008
  3. pmc U.S. medical resident familiarity with national tuberculosis guidelines
    Petros C Karakousis
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
    BMC Infect Dis 7:89. 2007
  4. ncbi request reprint Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
    Hum Vaccin 3:205-11. 2007
  5. ncbi request reprint Pandemic flu vaccine: are we doing enough?
    J D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland, USA
    Clin Pharmacol Ther 82:633-5. 2007
  6. ncbi request reprint Invasive pneumococcal infections among hospitalized children in Bamako, Mali
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD 21201, USA
    Pediatr Infect Dis J 23:642-9. 2004
  7. ncbi request reprint The causes of hospital admission and death among children in Bamako, Mali
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
    J Trop Pediatr 50:158-63. 2004
  8. ncbi request reprint Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults
    James D Campbell
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Infect Dis 186:1848-51. 2002
  9. ncbi request reprint Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants
    James D Campbell
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Pediatr Infect Dis J 21:822-6. 2002
  10. pmc Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine
    Jakub K Simon
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA
    Clin Vaccine Immunol 18:355-61. 2011

Detail Information

Publications22

  1. doi request reprint Antiretroviral prophylaxis for sexual and injection drug use acquisition of HIV
    James D Campbell
    Division of HIV AIDS Prevention, National Center for HIV, Viral Hepatitis, STD and TB Prevention, CDC Uganda, Entebbe, Uganda
    Am J Prev Med 44:S63-9. 2013
    ..PrEP is generally safe and effective and may be cost effective in a targeted population. Awareness and interest in PrEP are increasing. PrEP is an important new addition to HIV prevention services, but continued study is warranted...
  2. pmc Timing of therapy for latent tuberculosis infection among immigrants presenting to a U.S. public health clinic: a retrospective study
    Kathleen R Page
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
    BMC Public Health 8:158. 2008
    ..Current guidelines recommend screening and treatment for latent TB infection (LTBI) within 5 years of arrival to the U.S. This study evaluates the timing of LTBI therapy among immigrants presenting for care to a public health TB clinic...
  3. pmc U.S. medical resident familiarity with national tuberculosis guidelines
    Petros C Karakousis
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, USA
    BMC Infect Dis 7:89. 2007
    ..We assessed medical resident knowledge about tuberculosis diagnosis and early management based on American Thoracic Society guidelines...
  4. ncbi request reprint Safety, reactogenicity and immunogenicity of a recombinant protective antigen anthrax vaccine given to healthy adults
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
    Hum Vaccin 3:205-11. 2007
    ..Although an anthrax vaccine is currently licensed in the USA, better vaccines are desirable for both pre- and post-exposure prophylaxis...
  5. ncbi request reprint Pandemic flu vaccine: are we doing enough?
    J D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland, USA
    Clin Pharmacol Ther 82:633-5. 2007
    ..Below I discuss some truly phenomenal advances that have emerged from this newfound interest in pandemic influenza, to show that, yes, we are doing enough...
  6. ncbi request reprint Invasive pneumococcal infections among hospitalized children in Bamako, Mali
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, MD 21201, USA
    Pediatr Infect Dis J 23:642-9. 2004
    ..Prevention of invasive pneumococcal disease (IPD) in children is a global public health priority, and determination of the most common serotypes is crucial for vaccine development and implementation...
  7. ncbi request reprint The causes of hospital admission and death among children in Bamako, Mali
    James D Campbell
    University of Maryland School of Medicine, Center for Vaccine Development, Baltimore, Maryland 21201, USA
    J Trop Pediatr 50:158-63. 2004
    ..Prospective surveillance using microbiological data is needed to delineate the organism-specific burdens...
  8. ncbi request reprint Safety, reactogenicity, and immunogenicity of a tetravalent meningococcal polysaccharide-diphtheria toxoid conjugate vaccine given to healthy adults
    James D Campbell
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    J Infect Dis 186:1848-51. 2002
    ....
  9. ncbi request reprint Standard and alternative regimens of Haemophilus influenzae type b conjugate vaccine (polyribosylribitol phosphate-tetanus toxoid conjugate vaccine) elicit comparable antibody avidities in infants
    James D Campbell
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Pediatr Infect Dis J 21:822-6. 2002
    ....
  10. pmc Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine
    Jakub K Simon
    Center for Vaccine Development, University of Maryland School of Medicine, 685 West Baltimore Street, Room 480, Baltimore, MD 21201, USA
    Clin Vaccine Immunol 18:355-61. 2011
    ....
  11. ncbi request reprint A clinical study to assess the safety and immunogenicity of attenuated measles vaccine administered intranasally to healthy adults
    Jakub K Simon
    Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland, USA
    Hum Vaccin 3:54-8. 2007
    ..Mucosal administration of currently licensed measles vaccine has been proposed to address issues of needle safety and improve vaccine uptake...
  12. pmc Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults
    Karen L Kotloff
    Division of Infectious Disease and Tropical Pediatrics, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Infect Immun 70:2016-21. 2002
    ..We conclude that WRSS1 vaccine is remarkably immunogenic in doses ranging from 10(3) to 10(6) CFU but elicits clinical reactions that must be assessed in further volunteer trials...
  13. ncbi request reprint Safety and immunogenicity of a recombinant multivalent group a streptococcal vaccine in healthy adults: phase 1 trial
    Karen L Kotloff
    Department of Pediatrics, Center for Vaccine Development, University of Maryland School of Medicine, Baltimore 21201, USA
    JAMA 292:709-15. 2004
    ..Group A streptococcal infections and their sequelae represent a global health problem. Recent advances have allowed previous obstacles associated with group A streptococcal vaccine development to be overcome...
  14. ncbi request reprint Needle-free vaccine delivery
    Erin L Giudice
    Center for Vaccine Development, University of Maryland School of Medicine, 685 W Baltimore Street, Room 480, Baltimore, MD 21201, USA
    Adv Drug Deliv Rev 58:68-89. 2006
    ..Improved knowledge regarding the immune system and its responses to vaccination continues to inform vaccine technologies for needle-free vaccine delivery...
  15. ncbi request reprint The use of experimental drugs during national crisis
    Adil E Shamoo
    University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Account Res 10:69-84. 2003
  16. pmc Genotypic analysis of invasive Streptococcus pneumoniae from Mali, Africa, by semiautomated repetitive-element PCR and pulsed-field gel electrophoresis
    S M Harrington
    Department of Laboratory Medicine, National Institutes of Health, Bethesda, Maryland, USA
    J Clin Microbiol 45:707-14. 2007
    ..The data support that serotypes 2 and 5 were likely to be the result of dissemination of particular clones, some of which are responsible for invasive disease over a broad population range...
  17. ncbi request reprint Overview of vaccines and immunisation
    Myron M Levine
    Center for Vaccine Development, University of Maryland School of Medicine, Baltimore, Maryland 21201, USA
    Br Med Bull 62:1-13. 2002
  18. ncbi request reprint Rapid licensure of a new, inactivated influenza vaccine in the United States
    John J Treanor
    University of Rochester, Rochester, New York 14642, USA
    Hum Vaccin 1:239-44. 2005
    ..We evaluated a split virus TIV (Fluarix, GSK), to generate data supportive of a license application in the US...
  19. ncbi request reprint Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine
    Samba O Sow
    Centre pour le Développement des Vaccins, Mali CVD Mali
    Pediatr Infect Dis J 24:533-7. 2005
    ..Population-based, bacteriologically confirmed disease burden data aid decision makers in African countries pondering whether to introduce Haemophilus influenzae type b (Hib) immunization for infants...
  20. ncbi request reprint Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine
    John J Treanor
    Department of Medicine, University of Rochester, Rochester, NY, USA
    N Engl J Med 354:1343-51. 2006
    ..Influenza A (H5N1) viruses could cause a severe worldwide epidemic, with high attack rates, large numbers of deaths and hospitalizations, and wide disruption. Effective vaccines against these viruses in humans are urgently needed...
  21. doi request reprint Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans
    Kenneth M Zangwill
    University of California, Los Angeles, CA, USA
    J Infect Dis 197:580-3. 2008
    ..5-mug-dose groups had a MN GMT > or =1:40, respectively. Five months later, MN GMTs were significantly greater than those after the second dose. (Trial registration: Clinical Trials.gov identifier NCT00240968 .)...
  22. ncbi request reprint Vaccines to protect humans from pandemic avian influenza strains
    James D Campbell
    University of Maryland Center for Vaccine Development, Baltimore, USA
    Md Med 7:15-8. 2006
    ..No efficacy studies have yet been performed. Future efforts will be directed toward adjuvants, different routes of administration, newer manufacturing methods, and possibly new viral targets...